Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
The East Asian Parkinson Disease Genomics Consortium4474
Implications of the KIWE trial for low-income and lower-middle-income countries660
Multidisciplinary care for amyotrophic lateral sclerosis655
Lessons and future directions for GBA1-targeting therapies644
Dementia diagnosis in the anti-amyloid era615
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease551
Traumatic brain injury research: homogenising heterogeneity471
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply455
Correction to Lancet Neurol 2024; 23: 168–77399
Correction to Lancet Neurol 2022; 21: 42–52391
Correction to Lancet Neurol 2021; 20: 448–59383
The predictive value and clinical use of the neurological pupillary index – Authors' reply378
Pseudomedicine for sports concussions in the USA370
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r356
New therapies for Pompe disease: are we closer to a cure?346
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial284
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial281
Increasing diversity in dementia research277
Global burden of stroke: dynamic estimates to inform action262
Anti-CD19 CAR T cells for refractory myasthenia gravis258
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study257
Management of atherosclerotic extracranial carotid artery stenosis255
RAB32 mutation in Parkinson's disease254
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study244
The relevance of social and commercial determinants for neurological health236
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study206
A biological classification of Huntington's disease: the Integrated Staging System198
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study196
A chilly tale of dementia192
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study192
Trials in intracerebral haemorrhage: a path to success?190
A sensitive portrayal of a controversial condition189
A study in healing the wounds of trauma184
Epilepsy syndromes: an essential piece of the puzzle178
Beyond the modular brain177
Elia M Pestana Knight176
Delving into the human mind175
Albert Kwaku Akpalu164
A blood test for Alzheimer's disease: a step forward163
Considering the neurological health needs of LGBTQIA people152
Safe laboratory management of prions and proteopathic seeds150
Diana Cejas149
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply147
Movement disorders research in 2021: cracking the paradigm145
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri144
Gene therapy for X-linked myotubular myopathy: the challenges143
From stroke awareness to stroke action awareness143
Correction to Lancet Neurol 2022; 21: 284–94140
Correction to Lancet Neurol 2023; 22: 812–25135
Amyotrophic lateral sclerosis from genotoxins alone?133
A nasal CGRP receptor antagonist for acute migraine therapy131
Surrogate endpoints for progressive multifocal leukoencephalopathy128
Diversity and inclusion in neurosurgery127
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study125
Parkinson's disease is a recognisable and useful diagnostic entity125
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases124
Development of treatments for Down syndrome123
Aspiring to restore arm and hand function after stroke117
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro117
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial113
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial109
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment106
The prescription of valproate: risk of harm105
Encephalitis awareness: our ambitious global endeavour104
Better buildings for elderly people to thrive103
Poldi Wilbrink101
New results for risdiplam in spinal muscular atrophy99
Expansion of stenting indications in the USA94
Correction to Lancet Neurol 2021; 20: 687–8993
Neurological infections in 2023: surveillance and prevention93
Responsible innovation in neurology91
A proposal for equity neuroscience91
Jessica Ailani91
Multiple sclerosis in 2022: old players, new insights90
Correction to Lancet Neurol 2022; 21: 620–3190
Brain health in the Philippines90
Correction to Lancet Neurol 2024; 23: 110–2290
The International Brain Initiative: enabling collaborative science90
In search of Charcot's second sight89
Redefining use of MRI for patients with multiple sclerosis88
Detection of ionising radiation by the CNS: a case report88
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial86
Cognitive function in people with functional seizures85
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response83
0.029135942459106